Danazol

( DrugBank: Danazol / KEGG DRUG: Danazol )


5 diseases
IDDisease name (Link within this page)Number of trials
60Aplastic anemia3
63Idiopathic thrombocytopenic purpura1
64Thrombotic thrombocytopenic purpura1
IDDisease name (Link within this page)Number of trials
65Primary immunodeficiency2
285Fanconi anemia1

60. Aplastic anemia


Clinical trials : 245Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 391Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

64. Thrombotic thrombocytopenic purpura


Clinical trials : 92Drugs : 85 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 76 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

65. Primary immunodeficiency


Clinical trials : 500Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

285. Fanconi anemia


Clinical trials : 62Drugs : 93 - (DrugBank : 30) / Drug target genes : 30 - Drug target pathways : 144 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries